Biomed Group
Long/short equity, healthcare, biotech

KaloBios: An Undervalued Pharmaceutical Company With Remarkable Pipeline

KaloBios Pharmaceuticals (NASDAQ:KBIO) is a small-cap company focused on developing patient-targeted, first-in-class monoclonal antibodies using its proprietary Humaneered technology platform, with the intent to significantly improve the lives of seriously ill patients with difficult-to-treat diseases. Currently, the company's primary clinical focus is treating infectious and respiratory diseases and cancer. KaloBios has two antibodies in Phase II clinical testing for the treatment of severe/persistent asthma and cystic fibrosis (CF) and prevention of ventilation-associated pneumonia (VAP). It also has a third antibody in Phase I clinical testing for hematological malignancies.

The Company's Pipeline:

1. Humaneered technology - The Humaneered technology forms the basis of the company's drug discovery and development. The technology first uses conventional methods to identify initial antibody...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details